US 12,065,394 B2
Compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising thereof
Yong Tae Kwon, Seoul (KR); Srinivasrao Ganipisetti, Seoul (KR); Ki Woon Sung, Seoul (KR); Eui Jung Jung, Seoul (KR); Tae Hyun Bae, Seoul (KR); Su Ran Mun, Seoul (KR); and Chan Hoon Jung, Seoul (KR)
Assigned to Seoul National University R&DBFoundation, Seoul (KR)
Appl. No. 17/041,960
Filed by Seoul National University R&DB Foundation, Seoul (KR)
PCT Filed Mar. 26, 2019, PCT No. PCT/KR2019/003514
§ 371(c)(1), (2) Date Sep. 25, 2020,
PCT Pub. No. WO2019/190172, PCT Pub. Date Oct. 3, 2019.
Claims priority of provisional application 62/648,381, filed on Mar. 26, 2018.
Prior Publication US 2021/0024454 A1, Jan. 28, 2021
Int. Cl. C07C 215/50 (2006.01); A61P 3/04 (2006.01)
CPC C07C 215/50 (2013.01) [A61P 3/04 (2018.01)] 9 Claims
 
1. A compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
in Chemical Formula 1,
R1 is -L1-(phenyl),
R2 is hydrogen, or -L2-(phenyl),
L1 is C1-5 alkylene, and
L2 is C1-5 alkylene,
with the proviso that not both R1 and R2 are benzyl.